Innovent Biologics (HKEX: 01801) has dosed the first participant in a phase 3 clinical study of tigulixostat (IBI128), a xanthine ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE